<DOC>
	<DOCNO>NCT01538862</DOCNO>
	<brief_summary>This feasibility study see Granulocyte Colony Stimulating Factor ( GCSF ) effective treatment Dystrophic Epidermolysis Bullosa ( EB . ) Patients receive one course treatment study drug . The course 7 day length . After receive GCSF , patient follow 7 30 day follow discontinuation drug . Thirty day follow do via telephone communication patient family .</brief_summary>
	<brief_title>Efficacy Granulocyte Colony Stimulating Factor ( GCSF ) In Patients With Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Each patient must diagnosis severe generalize recessive dystrophic EB ( formerly know HallopeauSiemens RDEB ) confirm clinical criterion either follow : 1. transmission electron microscopy 2. immunofluorescence antigenic mapping type VII collagen monoclonal antibody stain 3 . COL7A1 mutational analysis The patient must history squamous cell carcinoma internal malignancy . Female patient pregnant . Patients active sign symptom infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>